Dapsone
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
The txgnn-pipeline skill is for pipeline management — not applicable here. Proceeding directly to generate the report from the Evidence Pack.
分析 Evidence Pack 的情況：
predicted_indications：空陣列 → 無 TxGNN 預測結果original_indications：空陣列 → 無原始適應症資料original_moa：[Data Gap]- 市場狀態：未上市，0 張許可證
- 安全性資料：全部 [Data Gap]
- 資料缺口：DG001（Blocking）、DG002（High）
由於 Evidence Pack 資料嚴重不足，以下為如實反映現況的評估報告：
DAPSONE：Evidence Pack 資料不完整，無法執行老藥新用評估
One-Sentence Summary
DAPSONE（DrugBank ID：DB00250）目前的 Evidence Pack 資料嚴重不足，無法完成完整的老藥新用評估。TxGNN 模型尚未產生任何新適應症預測，且原始適應症、作用機轉、安全性警語等關鍵欄位均存在資料缺口，需完成資料補充後方可進入正式評估流程。
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | No TxGNN prediction available |
| Evidence Level | L5 — No predictions or studies available |
| New Zealand Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Safety Considerations
Please refer to the package insert for safety information.
⚠️ Data Gap DG001 [Blocking]: Package insert warnings and contraindications have not been retrieved. This blocks entry into the safety pre-screening stage (S1). Remediation required: download and parse the official package insert PDF.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack for DAPSONE contains no TxGNN-predicted indications and two unresolved data gaps of Blocking and High severity. A repurposing assessment cannot be meaningfully conducted until these gaps are remediated.
To proceed, the following is needed:
- [Blocking — DG001] Retrieve package insert from the official regulatory authority website, extract warnings and contraindications, and re-run the safety pre-screening (S1) gate
- [High — DG002] Query DrugBank API for mechanism of action (MOA) to enable mechanism-relevance analysis for any future predicted indications
- [Required] Run TxGNN prediction pipeline for DB00250 to generate candidate new indications; without predictions, the repurposing rationale cannot be constructed
- [Required] Confirm original approved indications from authoritative sources (DrugBank, WHO, or approved regulatory filings) to establish the baseline for repurposing comparison
- [Optional] Conduct a drug interaction (DDI) query once the above data gaps are closed
Note: This report reflects the state of the Evidence Pack as of 2026-04-20. The absence of data does not indicate that DAPSONE lacks repurposing potential — only that the current data pipeline has not yet produced the inputs required for evaluation. Please re-run the evidence collection pipeline and regenerate this report once remediation steps are completed.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.